{"_id": "31326236|None", "id": "31326236", "infons": {}, "passages": [{"infons": {"journal": "Trends Pharmacol Sci. 2019 Aug;40(8):565-576. doi: 10.1016/j.tips.2019.06.003. ", "year": "2019", "article-id_pmc": "PMC6771436", "type": "title", "authors": "Paranjpe MD, Taubes A, Sirota M"}, "offset": 0, "text": "Insights into Computational Drug Repurposing for Neurodegenerative Disease.", "sentences": [], "annotations": [{"id": "1", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "Neurodegenerative Disease", "locations": [{"offset": 49, "length": 25}]}], "relations": []}, {"infons": {"type": "abstract"}, "offset": 76, "text": "Computational drug repurposing has the ability to remarkably reduce drug development time and cost in an era where these factors are prohibitively high. Several examples of successful repurposed drugs exist in fields such as oncology, diabetes, leprosy, inflammatory bowel disease, among others, however computational drug repurposing in neurodegenerative disease has presented several unique challenges stemming from the lack of validation methods and difficulty in studying heterogenous diseases of aging. Here, we examine existing approaches to computational drug repurposing, including molecular, clinical, and biophysical methods, and propose data sources and methods to advance computational drug repurposing in neurodegenerative disease using Alzheimer's disease as an example.", "sentences": [], "annotations": [{"id": "8", "infons": {"identifier": "MESH:D003920", "type": "Disease", "valid": true, "normalized": ["D003920"], "database": "ncbi_mesh", "normalized_id": "D003920", "biotype": "disease", "name": "Diabetes Mellitus", "accession": "@DISEASE_Diabetes_Mellitus"}, "text": "diabetes", "locations": [{"offset": 311, "length": 8}]}, {"id": "9", "infons": {"identifier": "MESH:D007918", "type": "Disease", "valid": true, "normalized": ["D007918"], "database": "ncbi_mesh", "normalized_id": "D007918", "biotype": "disease", "name": "Leprosy", "accession": "@DISEASE_Leprosy"}, "text": "leprosy", "locations": [{"offset": 321, "length": 7}]}, {"id": "10", "infons": {"identifier": "MESH:D015212", "type": "Disease", "valid": true, "normalized": ["D015212"], "database": "ncbi_mesh", "normalized_id": "D015212", "biotype": "disease", "name": "Inflammatory Bowel Diseases", "accession": "@DISEASE_Inflammatory_Bowel_Diseases"}, "text": "inflammatory bowel disease", "locations": [{"offset": 330, "length": 26}]}, {"id": "11", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative disease", "locations": [{"offset": 414, "length": 25}]}, {"id": "12", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative disease", "locations": [{"offset": 794, "length": 25}]}, {"id": "13", "infons": {"identifier": "MESH:D000544", "type": "Disease", "valid": true, "normalized": ["D000544"], "database": "ncbi_mesh", "normalized_id": "D000544", "biotype": "disease", "name": "Alzheimer Disease", "accession": "@DISEASE_Alzheimer_Disease"}, "text": "Alzheimer's disease", "locations": [{"offset": 826, "length": 19}]}], "relations": []}], "relations": [], "pmid": 31326236, "pmcid": null, "meta": {}, "date": "2019-08-01T00:00:00Z", "journal": "Trends Pharmacol Sci", "authors": ["Paranjpe MD", "Taubes A", "Sirota M"], "relations_display": []}
